We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+29.16%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$2.01B
AUM Growth
+$536M
Cap. Flow
+$287M
Cap. Flow %
14.23%
Top 10 Hldgs %
41.55%
Holding
100
New
24
Increased
34
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$52.5M
2
MDT icon
Medtronic
MDT
+$51M
3
ISRG icon
Intuitive Surgical
ISRG
+$45.3M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$37.4M
5
DXCM icon
DexCom
DXCM
+$32.3M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$63.9M
2
THC icon
Tenet Healthcare
THC
+$40.4M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$30.1M
4
BTSG icon
BrightSpring Health Services
BTSG
+$13.4M
5
PFE icon
Pfizer
PFE
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IKT icon
76
Inhibikase Therapeutics
IKT
$385M
$3.59M 0.18%
+1,750,000
New +$2.78M
VKTX icon
77
Viking Therapeutics
VKTX
$3.94B
$3.52M 0.17%
+100,000
New +$3.54M
GPCR icon
78
Structure Therapeutics
GPCR
$3.71B
$3.48M 0.17%
+50,000
New +$2.04M
SGHT icon
79
Sight Sciences
SGHT
$427M
$3.37M 0.17%
+425,000
New +$2.71M
GOSS icon
80
Gossamer Bio
GOSS
$88.9M
$3.1M 0.15%
+1,000,000
New +$2.85M
OSCR icon
81
Oscar Health
OSCR
$8.63B
$2.87M 0.14%
200,000
-350,000
-64% -$6.05M
LBRX
82
LB Pharmaceuticals
LBRX
$1.3B
$2.23M 0.11%
100,000
– –
EVMN
83
Evommune Inc
EVMN
$516M
$2.14M 0.11%
+125,000
New +$2.35M
TENX icon
84
Tenax Therapeutics
TENX
$60.6M
$2.04M 0.1%
167,000
– –
TNGX icon
85
Tango Therapeutics
TNGX
$4.44B
$1.77M 0.09%
+200,000
New +$1.72M
BCRX icon
86
BioCryst Pharmaceuticals
BCRX
$2.64B
$1.56M 0.08%
+200,000
New +$1.45M
A icon
87
Agilent Technologies
A
$42.2B
– –
-90,000
Closed -$11.6M
ACHC icon
88
Acadia Healthcare
ACHC
$2.9B
– –
-300,000
Closed -$7.43M
DYN icon
89
Dyne Therapeutics
DYN
$4.99B
– –
-800,000
Closed -$10.1M
ESPR
90
DELISTED
Esperion Therapeutics
ESPR
– –
-1,500,000
Closed -$3.98M
EXAS
91
DELISTED
Exact Sciences
EXAS
– –
-200,000
Closed -$10.9M
HOLX
92
DELISTED
Hologic
HOLX
– –
-100,000
Closed -$6.75M
INSM icon
93
PUT
Insmed
INSM
$29B
– –
-100,000
Closed -$14.4M
IQV icon
94
IQVIA
IQV
$40.1B
– –
-45,000
Closed -$8.55M
JNJ icon
95
Johnson & Johnson
JNJ
$626B
– –
-30,000
Closed -$5.56M
MCK icon
96
McKesson
MCK
$105B
– –
-15,000
Closed -$11.6M
NAMS icon
97
PUT
NewAmsterdam Pharma
NAMS
$3.3B
– –
-1,000,000
Closed -$28.4M
NVO
98
PUT
Novo Nordisk
NVO
$207B
– –
-400,000
Closed -$22.2M
PFE icon
99
Pfizer
PFE
$152B
– –
-500,000
Closed -$12.7M
PHVS icon
100
Pharvaris
PHVS
$2.41B
– –
-200,000
Closed -$4.99M
1 2 3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Integral Health Asset Management held 100 positions worth $2.01B, up 36% from $1.48B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Integral Health Asset Management deployed $287M of net new capital in Q4 2025, opening 24 new positions and adding to 34 existing holdings. Its largest new stake was DexCom: 500,000 shares worth $33.2M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $63.9M trimmed.

  • Integral Health Asset Management's largest Q4 2025 buy was DexCom: 500,000 shares worth $33.2M.
  • Integral Health Asset Management added most to Revolution Medicines in Q4 2025, an estimated $52.5M increase.
  • Integral Health Asset Management's biggest Q4 2025 reduction was Insmed, cutting an estimated $63.9M.
  • Integral Health Asset Management fully exited Pfizer in Q4 2025, selling an estimated $12.7M.
  • Integral Health Asset Management's ten largest holdings make up 42% of its $2.01B portfolio in Q4 2025.
  • Integral Health Asset Management opened 24 new positions and closed 14 in Q4 2025.
  • Integral Health Asset Management's portfolio value rose 36% quarter-over-quarter to $2.01B.

Based on Integral Health Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.